New York S 2625: Relates to enhancing patient access to medication assisted treatment for treatment of opioid disease

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S02625 Summary:

BILL NOS02625 

&nbsp

SAME ASSAME AS A03496

&nbsp

SPONSORFERNANDEZ

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Amd §§3331, 206 & 3381, Pub Health L; amd §§6801 & 6527, Ed L

&nbsp

Allows a licensed pharmacist to prescribe and order FDA-approved medication assisted therapy under a non-patient-specific regimen for the treatment of opioid use disease.

Go to top S02625 Actions:

BILL NOS02625 

&nbsp

01/21/2025REFERRED TO HEALTH

05/13/2025REPORTED AND COMMITTED TO FINANCE

01/07/2026REFERRED TO HEALTH

03/17/2026REPORTED AND COMMITTED TO HIGHER EDUCATION

Go to topS02625 Committee&nbspVotes:

Go to topS02625 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS02625 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 2625

 2025-2026 Regular Sessions

 IN SENATE

 January 21, 2025
 ___________

 Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
 printed to be committed to the Committee on Health

 AN ACT to amend the public health law and the education law, in relation
 to enhancing patient access to medication assisted treatment for
 treatment of opioid disease

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Section 3331 of the public health law is amended by adding
 2 a new subdivision 10 to read as follows:
 3 10. A pharmacist, in good faith, and in the usual course of profes-
 4 sional pharmacy practice, may prescribe, administer and dispense
 5 substances listed in schedules III, IV, and V for the treatment of
 6 opioid use disorders, as provided in titles III or V of this article.
 7 § 2. Section 6801 of the education law is amended by adding a new
 8 subdivision 10 to read as follows:
 9 10. (a) A licensed pharmacist may prescribe FDA-approved medication
 10 assisted therapy under a non-patient-specific regimen for the treatment
 11 of opioid use disease in accordance with subdivision twelve of section
 12 sixty-five hundred twenty-seven of this title and regulations promulgat-
 13 ed by the commissioner of health established pursuant to paragraph (x)
 14 of subdivision one of section two hundred six of the public health law
 15 in consultation with the commissioner.
 16 (b) A licensed pharmacist authorized to issue a prescription for medi-
 17 cation assisted treatment of opioid use disorder shall:
 18 (i) register with the federal Drug Enforcement Administration and
 19 complete the training required by Section 303 of the Controlled
 20 Substances Act (21 USC 823);
 21 (ii) provide information to the patient on the importance of having a
 22 primary health care practitioner, developed by the commissioner of
 23 health;

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD05761-03-5

 S. 2625 2

 1 (iii) report such administration by electronic transmission or facsim-
 2 ile to the patient's attending primary health care practitioner or prac-
 3 titioners, if any; and
 4 (iv) refer patient to provider or practice responsible for collaborat-
 5 ing in the non-patient-specific regimen.
 6 § 3. Subdivision 1 of section 206 of the public health law is amended
 7 by adding a new paragraph (x) to read as follows:
 8 (x) establish a statewide protocol for pharmacist prescribing of medi-
 9 cation assisted treatment of opioid use disorder, not later than ninety
 10 days after the effective date of this paragraph. A licensed pharmacist
 11 authorized to issue a prescription for medication assisted treatment of
 12 opioid use disorder shall register with the federal Drug Enforcement
 13 Administration and complete the training required by Section 303 of the
 14 Controlled Substances Act (21 USC 823).
 15 § 4. Paragraph (e) of subdivision 4 of section 3381 of the public
 16 health law, as amended by chapter 433 of the laws of 2021, is amended to
 17 read as follows:
 18 (e) A pharmacy registered under article one hundred thirty-seven of
 19 the education law may offer counseling and referral services to custom-
 20 ers purchasing hypodermic syringes for the purpose of: preventing
 21 injection drug abuse; the provision of drug treatment; preventing and
 22 treating hepatitis C; preventing drug overd